PENGARUH PROFITABILITAS DAN SOLVABILITAS TERHADAP HARGA SAHAM PERUSAHAAN TERINDEKS LQ45 DI BEI

The purpose of this study was to analyze the effect of independent variables, profitability proxied by Return On Equity (ROE) and solvency proxied by Debt to Assets Ratio (DAR) on the dependent variable, namely stock prices. The population in this study were 45 companies in the LQ45 category listed on the Indonesia Stock Exchange. Sampling in this study using purposive sampling method, namely as many as 31 companies that are consistently indexed LQ45 on the Indonesia Stock Exchange (IDX) during the 2015-2019 period with the amount of data processed after the outlier process as many as 129 samples. The analysis test model used in this hypothesis is multiple linear regression analysis. The results showed that profitability (ROE) had no effect on stock prices, solvency (DAR) had no effect on stock prices, and simultaneously (ROE) and solvency (DAR) had no effect on company stock prices. Keywords: Stock Price, Return on Equity (ROE), Debt to Assets Ratio (DAR)

856. Barriers to PrEP Implementation among Patient-Facing Staff in Three Urban Clinics

Background PrEP implementation has lagged in the US. The role of multidisciplinary staff in PrEP rollout has been neglected. We sought to identify barriers to PrEP implementation among 3 urban federally qualified health centers (FQHCs) in Connecticut that provide HIV and PrEP services in order to inform development of staff training. Methods A link to an anonymous survey was emailed to patient-facing staff members or posted at the end of staff trainings October 2020-April 2021. The survey requested demographics, duration of employment, and using 4 and 5 point Likert scales, ascertained knowledge and beliefs toward PrEP based on established scales, and perceived individual and systemic barriers to PrEP uptake. Results Among 101 respondents, 40% were 36-54yo, 22% were male, 68% were non-prescribing clinicians, and median duration of employment was 6 years (IQR 2-14). Among 32 (31%) prescribers (physicians, PAs, APRNs), 97% felt comfortable discussing sexual risk with patients, though 15% were not familiar with PrEP efficacy and safety data, 28% responded that PrEP use would encourage risky behaviors, 34% were concerned about side effects, 53% responded that educational and behavioral interventions should be attempted prior to prescribing PrEP, and 59% identified lack of provider training as a barrier. Among 69 (68%) non-prescribers, barriers to PrEP uptake included: patients don’t ask for PrEP (43%), lack of insurance (47%), lack of clinic guidelines/protocol (42%), and staff time for counseling (31%). Conclusion Prescribers and non-prescribers identified distinct individual and systemic barriers to PrEP uptake at FQHCs. Among prescribers, uncertainty regarding indications for and safety of PrEP exist, which will be addressed with targeted training. Non-prescribers identified the need for patient outreach, financial assistance, and counseling as the top priorities. The input of clinic multidisciplinary team members is essential to addressing barriers to PrEP implementation. Disclosures Sheela Shenoi, MD, MPH, Merck (Other Financial or Material Support, SS’s spouse worked for Merck pharmaceuticals 1997-2007 and retains company stock in his retirement account. There is no conflict of interest, but it is included in the interest of full disclosure.)

87. Infectious Disease Diversity, Equity, and Antiracism (ID2EA): A Dedicated Curriculum for Infectious Disease Professionals

Background Systemic bias in the health care system has adverse effects on health outcomes. Educational programs examining the relationship between structural racism and health inequities are needed to translate knowledge into equitable care. The Yale School of Medicine Infectious Disease (ID) Section designed and piloted an innovative Infectious Disease Diversity, Equity, and Anti-Racism (ID2EA) curriculum to better understand and confront these issues. Methods The ID Section collaborated with pedagogical experts to create a curriculum. A baseline survey of ID faculty and trainees was used to gauge relevant knowledge, attitudes, skills, and topics of interest to participants. The curriculum was designed as a “roadmap” of interactive sessions (“roadmap stops”) focused on topics identified by respondents. Evaluations were performed after events to guide curriculum development and monitor its acceptance and effectiveness. Results All respondents (n=28) to the baseline survey agreed that discussion of race and ethnicity should be integrated into medical training. Most respondents (96%) had experience or knowledge of racial microaggressions in the workplace. Fewer (75%) felt comfortable talking to patients about race and only 68% felt confident teaching learners how to decrease bias in care. The survey identified topics of highest priority to participants, including building trust with patients (75%), providing racially sensitive care (68%) and establishing dialogue with community members (57%). Roadmap stops were constructed based on these priorities, with sessions on race-based medical experimentation and inequities, racial segregation and its impact on health, medical mistrust, and a skill building session on improving patient-centered communication. On follow-up surveys (n=18-28), most participants (93%) saw the sessions as a valuable way to spend time and the majority (91%) reported an impact on their understanding of racism in healthcare; specific changes in thinking were qualitatively coded. Conclusion Our findings demonstrate the positive impact of a curriculum to help understand racism and inequities in medicine. Building and implementing a diversity, inclusion, and anti-racism curriculum in ID sections is feasible, beneficial, and valued. Disclosures Jaimie Meyer, MD, Gilead Sciences (Scientific Research Study Investigator) Sheela Shenoi, MD, MPH, Merck (Other Financial or Material Support, SS’s spouse worked for Merck pharmaceuticals 1997-2007 and retains company stock in his retirement account. There is no conflict of interest, but it is included in the interest of full disclosure.) Marjorie Golden, MD, Iterum Pharmaceuticals (Consultant)

Stock Valuation of Indonesia Pharmaceutical Company with COVID-19 Vaccination Development Prospects Amidst Pandemic Situation (Case Study of PT. Kalbe Farma, Tbk.)

As one of the world’s most populous countries with a fast-growing economy, Indonesia's market for pharmaceuticals has become very promising. COVID-19 pandemic that outbroken since early 2020 has brought a huge impact on the overall country condition while at the same time stimulate the growth of the pharmaceutical market as it is forecasted to grow at a CAGR of 6.3% between 2016 and 2021 according to IQVIA. This situation creates a reaction in the stock market especially of pharmaceutical companies that experienced an average increase of 67% since last year with its key driver of news regarding the distribution of Sinovac vaccine by some state-owned pharma companies as part of the national vaccination program. PT. Kalbe Farma, Tbk as one of the largest pharma companies in Indonesia is also accounting a positive growth over the years while also presented with bright prospects as a result of its strategic initiatives to collaborate with South Korea in developing COVID-19 vaccine and medication, named Genexine which is planned to be completed in Q3 2021. The possibility of success in this project might affect the company’s stock performance since it would result in bigger profitability for the company. In order to help investors to make a decision in this situation, the intrinsic value of the company stock is required. Therefore, conducting absolute and relative valuation are believed to be important in order to find the intrinsic value. This study examined absolute valuation using FCFF model and relative valuation using P/E and EV/EBITDA for KLBF. Result of the valuation suggested that the current stock price of IDR 1,445 is overvalued. The intrinsic value calculated from FCFF model is IDR 1,397 and based on the relative valuation models are IDR 1,330 and IDR 1,233 for EV/EBITDA and P/E ratio, respectively.

THE EFFECT OF INFLATION, INTEREST RATE, AND EXCHANGE RATE ON STOCK RETURNS IN FOOD & BEVERAGES COMPANIES

The purpose of this study was to determine the effect of technical information on stock returns partially. Risk and return are interrelated. The greater the return, the greater the risk obtained. However, if these risks are managed, the risks that will occur can be controlled properly. Several things need to be considered in making investment decisions, namely, by analyzing fundamental information and technical information, including inflation, exchange rates, interest rates, and their effect on stock returns. The method used in this study uses quantitative methods. This study indicates that inflation has a significant negative effect on stock returns, interest rates have no effect on stock returns, and the exchange rate has a significant negative effect on stock returns. Further researchers are expected to pay attention to the influence of other factors that can affect price movements and company stock returns.

Company Overview for 2017-2021: Apple vs Microsoft

The paper is devoted to company analysis and company stock trend analysis for two giants in electronics hardware and software market: Apple Inc. and Microsoft Corp. All data was derived from the companies’ annual reports and some other referenced websites. Analysis has been plotted using Python including and excluding the most recent year due to data availability.

Pengaruh Inflasi Dan BI Rate Terhadap Harga Saham Perusahaan LQ45 Pada Bursa Efek Indonesia

This research is motivated by a mismatch between theories regarding stock price movements that are influenced by inflation rates and BI Rate with conditions that occur in the field. In theory, when stock prices increase, it will be influenced by falling inflation and the BI Rate, and vice versa. But this is different from the conditions that occur in the field. This research aims to examine and determine the effect of inflation and BI Rate on the LQ45 company stock prices. This study uses the quantitative method by using the secondary data. From the results of the study using the t test, inflation has a tcount 0.828 and a Sig. 0.417. This shows that partially, inflation does not have a significant effect on stock prices. While the BI Rate has a value of -2.511 and a Sig. 0.020. This shows that partially, the BI Rate has a significant effect on stock prices. In correlation, inflation has a Sign value. (2-tailed) 0.068. This shows that in correlation, inflation does not have a significant relationship to the BI Rate. Simultaneously (F test), inflation and the BI Rate have a Fcount value of 5.005 and a Sig. (2-tailed) of 0.017. This shows that simultaneously, inflation and the BI Rate have a significant effect on stock prices.

Target-date funds and portfolio choice in 401(k) plans

Target-date funds in corporate retirement plans grew from $5 billion in 2000 to $734 billion in 2018, partly because federal regulation sanctioned these as default investments in automatic enrollment plans. We show that adopters delegated pension investment decisions to fund managers selected by plan sponsors. Inclusion of these funds in retirement saving menus raised equity shares, boosted bond exposures, curtailed cash/company stock holdings, and reduced idiosyncratic risk. The adoption of low-cost target-date funds may enhance retirement wealth by as much as 50% over a 30-year horizon.